72873-74-6 | SKF-86002

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$14.00	$10.00
2mg	98%	in stock	$17.00	$12.00
5mg	98%	in stock	$21.00	$15.00
10mg	98%	in stock	$26.00	$18.00
50mg	98%	in stock	$76.00	$53.00

Description

• Catalog Number: AC51503
• Chemical Name: SKF-86002
• CAS Number: 72873-74-6
• Molecular Formula: C16H12FN3S
• Molecular Weight: 297.35
• MDL Number: MFCD00869367
• SMILES: Fc1ccc(cc1)c1nc2n(c1c1ccncc1)CCS2

Computed Properties

• Complexity: 355
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 21
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 2
• XLogP3: 2.9

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

  The Biochemical journal 20130415

• Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

  Nature biotechnology 20111101

• Expression of TNF-alpha and IL-6 in HMC-1 cells treated with bisphenol A is attenuated by plant-originating glycoprotein (75 kDa) by blocking p38 MAPK.

  Naunyn-Schmiedeberg's archives of pharmacology 20100701

• Displacement assay for the detection of stabilizers of inactive kinase conformations.

  Journal of medicinal chemistry 20100114

• Phytoglycoprotein (75 kDa) isolated from Cudrania tricuspidata Bureau inhibits expression of interleukin-4 in the presence of di (2-ethylhexyl) phthalate via modulation of p38 mitogen-activated protein kinase in primary-cultured mouse thymocytes.

  Journal of applied toxicology : JAT 20090801

• p38 MAPK regulates ischemia-reperfusion-induced recruitment of leukocytes in the colon.

  Surgery 20090301

• Hyperosmolarity-induced dilation and epithelial bioelectric responses of guinea pig trachea in vitro: role of kinase signaling.

  The Journal of pharmacology and experimental therapeutics 20080701

• 6-Hydroxydopamine activates the mitochondrial apoptosis pathway through p38 MAPK-mediated, p53-independent activation of Bax and PUMA.

  Journal of neurochemistry 20080301

• Activation of p38MAPK contributes to expanded polyglutamine-induced cytotoxicity.

  PloS one 20080101

• Regulation of cardiotrophin-1 expression in mouse embryonic stem cells by HIF-1alpha and intracellular reactive oxygen species.

  Journal of cell science 20060315

• Low density lipoproteins inhibit the Na+/H+ antiport in human platelets via activation of p38MAP kinase.

  Biochemical and biophysical research communications 20060217

• Small molecular anti-cytokine agents.

  Medicinal research reviews 20060101

• p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice.

  American journal of physiology. Renal physiology 20050701

• Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin.

  Cancer research 20050301

• Lipopolysaccharide: a p38 MAPK-dependent disrupter of neutrophil chemotaxis.

  Microcirculation (New York, N.Y. : 1994) 20050101

• The discovery of novel chemotypes of p38 kinase inhibitors.

  Current topics in medicinal chemistry 20050101

• A Biacore biosensor method for detailed kinetic binding analysis of small molecule inhibitors of p38alpha mitogen-activated protein kinase.

  Analytical biochemistry 20040201

• Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.

  Journal of medicinal chemistry 20031023

• Role of the p38 MAPK pathway in cisplatin-based therapy.

  Oncogene 20030626

• p38 MAP kinase negatively regulates angiotensin II-mediated effects on cell cycle molecules in human coronary smooth muscle cells.

  Biochemical and biophysical research communications 20030606

• P38 MAPK: critical molecule in thrombin-induced NF-kappa B-dependent leukocyte recruitment.

  American journal of physiology. Heart and circulatory physiology 20030401

• Differential activation of the c-Jun N-terminal kinase pathway in arsenite-induced apoptosis and sensitization of chemically resistant compared to susceptible B-lymphoma cell lines.

  Toxicological sciences : an official journal of the Society of Toxicology 20020701

• From imidazoles to pyrimidines: new inhibitors of cytokine release.

  Journal of medicinal chemistry 20020620

• The effects of a cytokine suppressive anti-inflammatory drug on the output of prostaglandin E(2) and interleukin-1 beta from human fetal membranes.

  Molecular human reproduction 20020301

• Role of p38 mitogen-activated protein kinase in chemokine-induced emigration and chemotaxis in vivo.

  Journal of immunology (Baltimore, Md. : 1950) 20011201

• Transcriptional cross-talk between Smad, ERK1/2, and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-beta-induced aggrecan gene expression in chondrogenic ATDC5 cells.

  The Journal of biological chemistry 20010427

• Inhibition of p38 MAP kinase as a therapeutic strategy.

  Immunopharmacology 20000501

• Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.

  Bioorganic & medicinal chemistry letters 19981117

• p38 mitogen-activated protein kinase-dependent and -independent intracellular signal transduction pathways leading to apoptosis in human neutrophils.

  The Journal of biological chemistry 19980403

• Regulation of prostaglandin H synthase 2 expression in human monocytes by the marine natural products manoalide and scalaradial. Novel effects independent of inhibition of lipid mediator production.

  Biochemical pharmacology 19950928

• Effect of the beta-receptor blocking agent Visken on the action of coumarin.

  International journal of clinical pharmacology and biopharmacy 19751201